Fate Therapeutics Inc (FATE) Stock
NASDAQ · FATE
2.53
Fundamentals
Market cap
$303.15M
Price / Earnings ratio
-2.4x
Price / Sales ratio
46.5x
Price / Book ratio
2.0x
Return on assets
-0.4%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.0%
Debt / Equity ratio
N/A
Latest news
About Fate Therapeutics Inc
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
SectorHealthcare
IndustryBiotechnology
Employees161
CEODr. Bahram Valamehr M.B.A., Ph.D.
IPO DateOct 1, 2013
HeadquartersSan Diego, CA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Bahram Valamehr M.B.A., Ph.D. | President, CEO & Director | 1977 |
| Mr. Kamal Adawi M.S., MBA | CFO & Treasurer | 1979 |
| Ms. Cindy R. Tahl J.D. | Chief Legal & Compliance Officer and Corporate Secretary | 1973 |
| Ms. Jessica Francis | Senior Vice President of Human Resources & Operations | — |
| Dr. Martin Hosking | Head of Research | — |
| Dr. Tunde Babalola Ph.D. | Senior Vice President of Technical Operations & Quality | — |
| Mr. Ryan Douglas | Senior Director of Investor Relations & Business Development | — |
| Mr. Andrew Henry | Senior Vice President of Clinical Operations | 1964 |
| Dr. Yu Cai J.D., Ph.D. | Head of Intellectual Property & Assistant General Counsel | — |
| Ms. Kate Duvall | Corporate Controller | — |
Fundamentals
Valuation
Market cap$303.15M
Price-to-sales ratio46.51
Price-to-book value1.97
Price-earnings ratio-2.40
Return on Equity-59.00%
Return on SalesN/A
Return on AssetsN/A
PEG ratio0.00
Earnings Per Share
Earnings Per Share$-1.05
Income Statement
Average volume1,295,712
EBITDA$-117.42M
1 year high (52w)$3.23
1 year low (52w)$0.94
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A



